【直报网5月25日讯】（中国证券报）根据北京产权交易所公告，山东聊城阿华制药有限公司47.294%股权正在挂牌交易，挂牌价格共计4825万元，转让方为东阿阿胶。按照发展补血、滋补、保健业务的战略，东阿阿胶将逐步实现非主业退出。

CNDSN may 25 news, China Securities Journal according to the announcement of the China Beijing Equity Exchange, the stake in Shandong Liaocheng Ahua Pharmaceutical Co., Ltd. 47.294% is listed transactions, a total of 4825 million yuan price listing, the transferor for donkey hide gelatin. According to the development of blood nourishing, health care, business strategy, Dong'e E-Jiao will gradually realize the non core business exit.

转让聊城制药股权

Transfer Liaocheng pharmaceutical stake

资料显示，山东聊城阿华制药有限公司成立于1998年，注册资本3166万元，经营范围为药用辅料的生产销售等。裕昌投资控股集团有限公司持有50%股权，东阿阿胶股份有限公司持有47.294%股权。此次转让完成后，东阿阿胶将不再持有标的公司股权。

Statistics show that Liaocheng Shandong A Hua Pharmaceutical Co., Ltd. was established in 1998, the registered capital of 31660000 yuan, the operating range of pharmaceutical accessories production and sales, etc.. Yu Chang Investment Holdings Limited holds 50% stake, Dong'e E-Jiao Limited by Share Ltd holds a 47.294% stake. The transfer is completed, Dong'e E-Jiao will no longer hold targets equity.

2014年度聊城制药实现营业收入5970.51万元，净利润93.84万元。2015年一季度，实现营业收入1549.31万元，净利润53.84万元。聊城制药资产总计7365.79万元，负债总计626.74万元，所有者权益为6739.06万元。经评估后，净资产为1.02亿元。转让标的对应评估值为4823.87万元。

2014 annual Liaocheng pharmaceutical achieved operating income of 59705100 yuan, net profit of 938400 yuan. 2015 first quarter, operating income of 15493100 yuan, net profit of 538400 yuan. Liaocheng pharmaceutical assets totaled 73657900 yuan, total liabilities of 6267400 yuan, the owner's equity of 67390600 yuan. After the assessment, net assets of 102000000 yuan. The corresponding assessment value of the assignment is 48238700 yuan.

此次转让要求，意向受让方应为中国境内依法设立并有效存续的内资企业法人，具备良好的财务状况，其2014年度经审计的净资产不低于2亿元；项目不接受联合受让。

The request for transfer, the intention of the transferee should be within the territory of the people's Republic of China established in accordance with the law and validly existing domestic corporate, have a good financial situation, the year 2014 the audited net assets of not less than 200 million yuan; project does not accept joint transferee.

据了解，聊城制药主要生产微晶纤维素、羧甲淀粉钠、硬脂酸镁、薄膜包衣预混剂、预胶化淀粉、糊精、药用淀粉、羟丙基纤维素、羟丙基甲基纤维素、甲基纤维素、乙基纤维素、羧甲基纤维素钠、二氧化硅等系列产品。

It is understood that Liaocheng major pharmaceutical production of microcrystalline cellulose, carboxyl methyl starch sodium, stearic acid magnesium, film coating pre mixed agents, pre gelatinized starch, dextrin, medicinal starch, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, ethyl cellulose, carboxymethyl cellulose sodium, silica and other series products.

退出非主业

Quit the main industry

早在3月19日，东阿阿胶发布公告称，按照东阿阿胶聚焦补血、滋补、保健业务的发展战略，拟对聊城制药其股权进行处置，实现非主业策略性退出。

As early as March 19, donkey hide gelatin announcement said, according to Dong Ejiao focusing blood, nourishing, health care business development strategy, intends to dispose of Liaocheng pharmaceutical equity, to withdraw from the non core business strategy.

东阿阿胶认为，此次交易若顺利完成，将形成一定投资收益，对公司2015年度利润产生一定影响。更为重要的是，通过此次交易，实现非主业退出，优化调整公司产业结构，将进一步聚焦补血、滋补、保健业务，有利于主业的持续健康发展。

Donkey hide gelatin believes that the transaction if successfully completed, will form a certain investment income, have a certain impact on earnings for the year 2015. More important is, through the transaction, to withdraw from the non core business, adjust and optimize the industrial structure of the company, will further focus on enriching the blood, nourishing, health care services, conducive to the industry sustained and healthy development of the.

从业绩表现上看，东阿阿胶一季度收入同比增长51.29%，净利润同比增长23.16%，主要是阿胶系列产品去年大幅提价所致。业内人士认为，公司一季度经营开局良好，随着产品提价后销售陆续恢复，预计2015年主业收入有望增长20%以上。

From the point of view of the performance, the donkey hide gelatin a quarter year-on-year revenue growth 51.29%, net profit grew 23.16%, mainly products Ejiao sharply last year, a result of price increases. The industry believes that the first quarter of the company started well, with the product price after sales continue to resume, is expected in 2015 the main industry is expected to grow more than 20% of the main industry.

目前，东阿阿胶已经形成了阿胶、人参、鹿茸等滋补保健产品线。按照发展战略规划，公司将围绕“补血、滋补、保健”战略发展方向，由补血市场向滋补、保健类大健康市场拓展。

At present, Dong'e has formed a gelatin, gelatin, ginseng antler tonic health care product line. According to the development strategy planning, the company will focus on the strategic direction of "enriching the blood, nourishing, health care", by the blood market to nourishing health care, health market expansion.

4月28日，东阿阿胶公告，计划以自有资金投资2989万元，与爱之味健康生技食品有限公司、台湾第一生化健康生技食品有限公司合资成立东润堂健康生技股份有限公司；并计划以自有资金投资2550万元，与上述两家公司合资成立东润堂国际贸易股份有限公司。

April 28, donkey hide gelatin announcement, plans to its own funds investment 29.89 million yuan, born in biotechnology Foods Co., Ltd., Taiwan first biochemical health and love the taste of health biotech Food Co., Ltd., a joint venture Dongrun hall healthy Biotechnology Co., Ltd.; and plan of its own funds to investment 25.5 million yuan, is a joint venture with the two companies set up Dongrun Tang International Trading Co., Ltd..

公司称，将借助于爱之味健康生技食品有限公司和台湾第一生化健康生技食品有限公司在健康饮品方面的经验介入保健饮品领域，此次投资有利于补充完善公司产品结构，开拓新的业务领域。业内人士认为，介入保健类市场，将有助于公司发展新业务，拓展新的成长空间。▲

The company said, will help to love the taste of health students technical Food Co., Ltd. and Taiwan first biochemical health students technical Food Co., Ltd. in health drinks experience involved in the field of health drinks, the investment will help supplement improve the product structure, develop new business areas. Industry believes that interventional health care market, will help the company develop new business, expand new growth space. 3

责任编辑：小申

Editor: Little Shen